Immunocore Holdings plc (ADR)
General ticker "IMCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Immunocore Holdings plc (ADR) follows the US Stock Market performance with the rate: 4.0%.
Estimated limits based on current volatility of 2.3%: low 31.80$, high 33.27$
Factors to consider:
- Total employees count: 524 (+6.3%) as of 2025
- US accounted for 73.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing issues, Sales and marketing delays, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [26.09$, 48.95$]
- 2026-12-31 to 2027-12-31 estimated range: [26.08$, 49.21$]
Financial Metrics affecting the IMCR estimates:
- Negative: with PPE of -52.0 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of -0.44 <= 2.37
- Negative: 34.41 < Shareholder equity ratio, % of 35.70 <= 42.26
- Positive: -13.52 < Operating profit margin, % of -10.18
- Negative: 0.33 < Interest expense per share per price, % of 0.68
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Inventory ratio change, % of -0.21 <= 0
Short-term IMCR quotes
Long-term IMCR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £249.43MM | £310.20MM | £400.02MM |
| Operating Expenses | £309.08MM | £380.66MM | £445.37MM |
| Operating Income | £-59.65MM | £-70.46MM | £-45.35MM |
| Non-Operating Income | £-1.24MM | £17.52MM | £26.25MM |
| Interest Expense | £4.08MM | £18.84MM | £12.17MM |
| R&D Expense | £129.42MM | £177.44MM | £204.47MM |
| Income(Loss) | £-60.89MM | £-52.94MM | £-19.10MM |
| Taxes | £-5.60MM | £-1.85MM | £16.41MM |
| Net Income(Loss)* | £-55.29MM | £-51.09MM | £-35.51MM |
| Stockholders Equity | £368.84MM | £360.72MM | £381.03MM |
| Inventory | £3.56MM | £5.45MM | £6.74MM |
| Assets | £597.00MM | £1,009.51MM | £1,067.27MM |
| Operating Cash Flow | £2.33MM | £26.06MM | £-7.97MM |
| Capital expenditure | £4.29MM | £5.17MM | £3.23MM |
| Investing Cash Flow | £-4.29MM | £-355.13MM | £-12.16MM |
| Financing Cash Flow | £27.18MM | £343.88MM | £9.20MM |
| Earnings Per Share** | £-1.13 | £-1.02 | £-0.71 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.